Developer docs
API playgroundTry for free, no card

Search company profiles

Phenotypeca

Full company profile

uuid000dr9d

Namestring
Phenotypeca
Legal namestring
Phenotypeca Ltd.
Websiteurl
phenotypeca.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Phenotypeca is a UK-based synthetic biology company founded in 2018 and headquartered at BioCity Nottingham that specialises in yeast strain optimisation for recombinant protein manufacturing. The company's proprietary platform uses Quantitative Trait Loci (QTL) technology, an evolutionary breeding method combined with whole-genome functional genomics, to develop high-performance Saccharomyces cerevisiae production strains that deliver 5-20 fold improvements in protein titre compared to traditional genetic engineering or mutagenesis approaches. The platform optimises multiple production traits simultaneously across the entire genome rather than single genes, with all strains animal-free and antibiotic-free by default for regulatory-friendly manufacturing.

The company operates across three product lines. The biosimilars portfolio includes Semaglutide (GLP-1 analogue for obesity/diabetes), Recombinant Albumin (rHSA and rBSA for plasma expansion and cell culture media), and Sargramostim (recombinant GM-CSF for acute radiation syndrome stockpiling). The biological therapeutics pipeline targets VHH antibody therapies for autoimmune conditions (plaque psoriasis, atopic dermatitis), multi-valent HPV vaccine candidates, and a neoantigen cancer vaccine platform. The peptides business supplies recombinant peptides for skincare and consumer health applications where chemical synthesis is uneconomical. Phenotypeca also offers custom strain optimisation services and downstream process support on a project basis.

The company monetises through four revenue streams: territory-specific licensing of patent-protected biosimilar strains with technology transfer support, custom strain development services priced per project, direct API supply to qualified public sector or military buyers, and peptide supply for consumer health brands. Customer segments span pharmaceutical and biotechnology companies, CDMOs, government and military agencies, and beauty/consumer health brands. The company holds granted patents on its QTL optimisation methods and key genetic alleles for each biosimilar, and is supported by the Bill & Melinda Gates Foundation for recombinant albumin development aimed at vaccine accessibility in low and middle-income countries.

Short descriptiontext

Phenotypeca is a UK-based synthetic biology company that develops patented yeast strain optimisation technology (QTL) for recombinant protein manufacturing, licensing biosimilar strains (semaglutide, albumin, sargramostim) and offering custom strain services to pharmaceutical, biotech, government, and consumer health clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNottingham, United Kingdom
HQ citystring
Nottingham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
yeast strain engineering, biosimilar development, biopharmaceutical manufacturing, recombinant protein production, synthetic biology
Industry3 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAHAB
Recombinant Protein Biosimilars (hormones, enzymes, cytokines)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Biosimilar Licensing
TypeLicensing Royalties
Description

License premium biosimilar strains (Semaglutide, Sargramostim, Recombinant Albumin) to pharmaceutical partners for development and commercialisation. Territory-specific exclusive or non-exclusive licensing with technology transfer support and ongoing API supply options.

phenotypeca.com
2Custom Strain Development Services
TypeProfessional Services
Description

Bespoke strain optimisation service with clearly defined stages: initial evaluation (feasibility and titre), breeding cycles and optimisation, stability testing and cell bank creation. Priced on per-project basis.

phenotypeca.com
3Peptide Supply
TypeHardware Sales
Description

Bulk recombinant peptide production and supply for skincare, beauty, supplements, and consumer health. Custom development and exclusive access to proprietary peptide pipeline.

phenotypeca.com
4Process Support Services
TypeProfessional Services
Description

Technical troubleshooting and support for downstream processing challenges, regulatory submissions, and manufacturing optimisation.

phenotypeca.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom strain development projects
ModelOtherBilling cadenceMulti-year contract
Notes

Per-project pricing for strain optimisation services including feasibility evaluation, breeding cycles, and cell bank creation. Specific stages have defined timeframes: 4-6 weeks design/implementation, 10-12 weeks breeding optimisation, 12-16 weeks stability testing.

phenotypeca.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Phenotypeca develops and licenses high-performance Saccharomyces cerevisiae production strains for recombinant protein manufacture using its proprietary Quantitative Trait Locus (QTL) strain optimisation platform. The company licenses biosimilars (Semaglutide, Recombinant Albumin, Sargramostim), develops biological therapeutics (VHH antibodies, multi-valent vaccines), supplies recombinant peptides for skincare and consumer health, and provides custom strain optimisation and process support services to pharmaceutical, biotech, CDMO and government clients.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Phenotypeca operates as a biotechnology company built around its proprietary QTL (Quantitative Trait Locus) strain optimisation technology platform. The company's portfolio consists of three interconnected product lines: (1) Biosimilars including Semaglutide, Recombinant Albumin, and Sargramostim, which are produced using QTL-optimised yeast strains for superior yield and cost efficiency; (2) Biological Therapeutics encompassing VHH antibody therapies, HPV vaccine candidates, and a neoantigen cancer vaccine platform; and (3) Peptides for skincare and consumer health applications. The QTL platform underpins all offerings, enabling multi-parameter whole-genome optimisation through evolutionary breeding. Services include custom strain optimisation and process support to help partners overcome manufacturing challenges.

Product and service9 records
1Semaglutide Biosimilar
CategoryBiosimilar
Description

GLP-1 analogue biosimilar for obesity and diabetes care, developed using QTL strain optimisation for high-yield, low-cost semi-recombinant manufacturing; offered to pharmaceutical partners via licensing.

2Recombinant Albumin
CategoryBiosimilar
Description

Animal-free recombinant human serum albumin (rHSA) and recombinant bovine serum albumin (rBSA) produced in Saccharomyces cerevisiae for plasma expansion, cell culture media, and biopharmaceutical formulations; offered to CDMOs and pharma partners via licensing and supply.

3Sargramostim Biosimilar
CategoryBiosimilar
Description

Recombinant GM-CSF biosimilar for acute radiation syndrome (ARS), optimised for national stockpiling against nuclear attack or accident and licensed to government/military customers.

4Recombinant Peptides
CategoryBiological Product
Description

Recombinant peptides for skincare and consumer health applications, supplied in bulk at commercial scale using QTL-optimised yeast strains for large or complex peptides that are uneconomical to produce via chemical synthesis.

5VHH Antibody Therapy
CategoryBiological Therapeutic
Description

Single-domain antibody (VHH/sdAb) therapeutics targeting plaque psoriasis and atopic dermatitis, developed using QTL-optimised Saccharomyces cerevisiae strains for superior performance; offered via co-development or licensing partnerships.

6HPV Vaccine Candidate
CategoryBiological Therapeutic
Description

Human papillomavirus vaccine candidate developed using multi-valent vaccine platform technology to overcome manufacturing constraints and enable lower-cost or breakthrough-efficacy vaccines.

7Neoantigen Cancer Vaccine Platform
CategoryBiological Therapeutic
Description

Personalised cancer vaccine platform leveraging evolutionary functional genomics for novel therapeutic development.

8Custom Strain Optimisation Services
CategoryService
Description

Bespoke strain development services using QTL technology to optimise upstream performance, reduce downstream processing complexity, and achieve cost-efficient bioprocesses; priced per project across feasibility (4-6 weeks), breeding optimisation (10-12 weeks) and stability testing (12-16 weeks) stages.

9Process Support Services
CategoryService
Description

Technical troubleshooting support for biologics manufacturing challenges including low titres, scale-up issues, solubility problems, downstream processing, regulatory submissions, and CMC failures.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Codexis is a protein engineering company using directed evolution and computational biology to develop optimised enzymes and strains for pharmaceutical manufacturing. Its CodeEvolver platform is thematically comparable to Phenotypeca's QTL evolution-based strain optimisation, and serves overlapping pharmaceutical/biotech customers.

TypeBroad incumbent
Description

Amyris is a synthetic biology company that engineered yeast strains for industrial-scale production of ingredients (although now largely restructured). Its historical work on yeast-based recombinant production is thematically comparable to Phenotypeca's yeast platform, particularly as a cautionary case study on scaling such platforms.

3GlycoFi (Merck)
TypeBroad incumbent
Description

GlycoFi, acquired by Merck in 2006, was a pioneer in glycoengineered yeast strains for therapeutic protein production. As a successful exit precedent in yeast-based protein expression platform companies, it represents a strategic comparable for Phenotypeca's category and exit trajectory.

4Cobra Biologics
TypeEmerging player
Description

Cobra Biologics is a CDMO specialising in recombinant protein and viral vector production using microbial (E. coli and yeast) and mammalian systems. Several Phenotypeca team members previously worked at Cobra, and the company represents a comparable microbial CDMO / contract manufacturing model for the same customer base.

TypeBroad incumbent
Description

Ginkgo Bioworks is a large, publicly-traded synthetic biology platform company serving pharma, agriculture, and industrial biotech customers with cell engineering services. It represents a broader, well-capitalised platform competitor to Phenotypeca's yeast strain optimisation offering, with much greater scale and scope.

TypeEmerging player
Description

Bicycle Therapeutics is a UK-based biotechnology company developing peptide-based therapeutics (bicyclic peptides). Comparable to Phenotypeca's peptide supply and novel therapeutic development strategy, with a similar UK origin and peptide/biologic focus.

7Albumedix
TypeDirect peer
Description

Albumedix (formerly Novozymes Biopharma / Delta Biotechnology) is a leading supplier of recombinant human albumin (rHSA) produced in Saccharomyces cerevisiae — directly comparable to Phenotypeca's recombinant albumin strain licensing business. Their commercial product Recombumin is the closest commercial competitor in the yeast-based recombinant albumin market.

TypeRegional player
Description

e-Therapeutics is a UK-based drug discovery company previously led by Phenotypeca CEO Johnny Cordiner. While operating in a different therapeutic modality (network pharmacology and siRNA), it represents a relevant comparable for understanding the CEO's strategic playbook and the UK biotech capital markets environment.

9Delta Biotechnology
TypeDirect peer
Description

Delta Biotechnology was the original commercial developer of recombinant human serum albumin in yeast. Now operating under Albumedix, it represents the historical reference technology for the recombinant albumin category Phenotypeca is targeting with its QTL-optimised strains.

TypeDirect peer
Description

Novozymes Biopharma (now part of Novonesis) is a long-established yeast-based recombinant protein manufacturer with decades of commercial biopharmaceutical supply. Comparable to Phenotypeca in yeast expression platform technology and recombinant protein production expertise, and a noted previous employer of several Phenotypeca team members.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phenotypeca

Biopharmaceutical Manufacturingphenotypeca.com

Phenotypeca is a UK-based synthetic biology company that develops patented yeast strain optimisation technology (QTL) for recombinant protein manufacturing, licensing biosimilar strains (semaglutide, albumin, sargramostim) and offering custom strain services to pharmaceutical, biotech, government, and consumer health clients.

What Phenotypeca does

Phenotypeca is a UK-based synthetic biology company founded in 2018 and headquartered at BioCity Nottingham that specialises in yeast strain optimisation for recombinant protein manufacturing. The company's proprietary platform uses Quantitative Trait Loci (QTL) technology, an evolutionary breeding method combined with whole-genome functional genomics, to develop high-performance Saccharomyces cerevisiae production strains that deliver 5-20 fold improvements in protein titre compared to traditional genetic engineering or mutagenesis approaches. The platform optimises multiple production traits simultaneously across the entire genome rather than single genes, with all strains animal-free and antibiotic-free by default for regulatory-friendly manufacturing.

The company operates across three product lines. The biosimilars portfolio includes Semaglutide (GLP-1 analogue for obesity/diabetes), Recombinant Albumin (rHSA and rBSA for plasma expansion and cell culture media), and Sargramostim (recombinant GM-CSF for acute radiation syndrome stockpiling). The biological therapeutics pipeline targets VHH antibody therapies for autoimmune conditions (plaque psoriasis, atopic dermatitis), multi-valent HPV vaccine candidates, and a neoantigen cancer vaccine platform. The peptides business supplies recombinant peptides for skincare and consumer health applications where chemical synthesis is uneconomical. Phenotypeca also offers custom strain optimisation services and downstream process support on a project basis.

The company monetises through four revenue streams: territory-specific licensing of patent-protected biosimilar strains with technology transfer support, custom strain development services priced per project, direct API supply to qualified public sector or military buyers, and peptide supply for consumer health brands. Customer segments span pharmaceutical and biotechnology companies, CDMOs, government and military agencies, and beauty/consumer health brands. The company holds granted patents on its QTL optimisation methods and key genetic alleles for each biosimilar, and is supported by the Bill & Melinda Gates Foundation for recombinant albumin development aimed at vaccine accessibility in low and middle-income countries.

Phenotypeca firmographics

Firmographics
Name
Phenotypeca
Legal name
Phenotypeca Ltd.
Website
https://phenotypeca.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Phenotypeca is a UK-based synthetic biology company that develops patented yeast strain optimisation technology (QTL) for recombinant protein manufacturing, licensing biosimilar strains (semaglutide, albumin, sargramostim) and offering custom strain services to pharmaceutical, biotech, government, and consumer health clients.
Ownership category
akta.pro rank

Phenotypeca industry classification

Industry
Product category
Biopharmaceutical Manufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAHAB
Recombinant Protein Biosimilars (hormones, enzymes, cytokines)

Keywords

  • Yeast strain engineering
  • Biosimilar development
  • Biopharmaceutical manufacturing
  • Recombinant protein production
  • Synthetic biology

Where Phenotypeca is headquartered

Location

Headquarters

HQ city
Nottingham
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Phenotypeca business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biosimilar Licensing: License premium biosimilar strains (Semaglutide, Sargramostim, Recombinant Albumin) to pharmaceutical partners for development and commercialisation. Territory-specific exclusive or non-exclusive licensing with technology transfer support and ongoing API supply options.
  2. Custom Strain Development Services: Bespoke strain optimisation service with clearly defined stages: initial evaluation (feasibility and titre), breeding cycles and optimisation, stability testing and cell bank creation. Priced on per-project basis.
  3. Peptide Supply: Bulk recombinant peptide production and supply for skincare, beauty, supplements, and consumer health. Custom development and exclusive access to proprietary peptide pipeline.
  4. Process Support Services: Technical troubleshooting and support for downstream processing challenges, regulatory submissions, and manufacturing optimisation.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom strain development projects

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Phenotypeca product offering

Product offering

Core offering

Phenotypeca develops and licenses high-performance Saccharomyces cerevisiae production strains for recombinant protein manufacture using its proprietary Quantitative Trait Locus (QTL) strain optimisation platform. The company licenses biosimilars (Semaglutide, Recombinant Albumin, Sargramostim), develops biological therapeutics (VHH antibodies, multi-valent vaccines), supplies recombinant peptides for skincare and consumer health, and provides custom strain optimisation and process support services to pharmaceutical, biotech, CDMO and government clients.

Product overview

Phenotypeca operates as a biotechnology company built around its proprietary QTL (Quantitative Trait Locus) strain optimisation technology platform. The company's portfolio consists of three interconnected product lines: (1) Biosimilars including Semaglutide, Recombinant Albumin, and Sargramostim, which are produced using QTL-optimised yeast strains for superior yield and cost efficiency; (2) Biological Therapeutics encompassing VHH antibody therapies, HPV vaccine candidates, and a neoantigen cancer vaccine platform; and (3) Peptides for skincare and consumer health applications. The QTL platform underpins all offerings, enabling multi-parameter whole-genome optimisation through evolutionary breeding. Services include custom strain optimisation and process support to help partners overcome manufacturing challenges.

Differentiator

Problem solved

Functional benefit

Products and services

  • Semaglutide Biosimilar GLP-1 analogue biosimilar for obesity and diabetes care, developed using QTL strain optimisation for high-yield, low-cost semi-recombinant manufacturing; offered to pharmaceutical partners via licensing.
  • Recombinant Albumin Animal-free recombinant human serum albumin (rHSA) and recombinant bovine serum albumin (rBSA) produced in Saccharomyces cerevisiae for plasma expansion, cell culture media, and biopharmaceutical formulations; offered to CDMOs and pharma partners via licensing and supply.
  • Sargramostim Biosimilar Recombinant GM-CSF biosimilar for acute radiation syndrome (ARS), optimised for national stockpiling against nuclear attack or accident and licensed to government/military customers.
  • Recombinant Peptides Recombinant peptides for skincare and consumer health applications, supplied in bulk at commercial scale using QTL-optimised yeast strains for large or complex peptides that are uneconomical to produce via chemical synthesis.
  • VHH Antibody Therapy Single-domain antibody (VHH/sdAb) therapeutics targeting plaque psoriasis and atopic dermatitis, developed using QTL-optimised Saccharomyces cerevisiae strains for superior performance; offered via co-development or licensing partnerships.
  • HPV Vaccine Candidate Human papillomavirus vaccine candidate developed using multi-valent vaccine platform technology to overcome manufacturing constraints and enable lower-cost or breakthrough-efficacy vaccines.
  • Neoantigen Cancer Vaccine Platform Personalised cancer vaccine platform leveraging evolutionary functional genomics for novel therapeutic development.
  • Custom Strain Optimisation Services Bespoke strain development services using QTL technology to optimise upstream performance, reduce downstream processing complexity, and achieve cost-efficient bioprocesses; priced per project across feasibility (4-6 weeks), breeding optimisation (10-12 weeks) and stability testing (12-16 weeks) stages.
  • Process Support Services Technical troubleshooting support for biologics manufacturing challenges including low titres, scale-up issues, solubility problems, downstream processing, regulatory submissions, and CMC failures.

Companies that use Phenotypeca

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Phenotypeca technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Phenotypeca partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Phenotypeca competitors and assessment

Company assessment

Emerging players

  • Codexis: Codexis is a protein engineering company using directed evolution and computational biology to develop optimised enzymes and strains for pharmaceutical manufacturing. Its CodeEvolver platform is thematically comparable to Phenotypeca's QTL evolution-based strain optimisation, and serves overlapping pharmaceutical/biotech customers.
  • Cobra Biologics: Cobra Biologics is a CDMO specialising in recombinant protein and viral vector production using microbial (E. coli and yeast) and mammalian systems. Several Phenotypeca team members previously worked at Cobra, and the company represents a comparable microbial CDMO / contract manufacturing model for the same customer base.
  • Bicycle Therapeutics: Bicycle Therapeutics is a UK-based biotechnology company developing peptide-based therapeutics (bicyclic peptides). Comparable to Phenotypeca's peptide supply and novel therapeutic development strategy, with a similar UK origin and peptide/biologic focus.

Broad incumbents

  • Amyris: Amyris is a synthetic biology company that engineered yeast strains for industrial-scale production of ingredients (although now largely restructured). Its historical work on yeast-based recombinant production is thematically comparable to Phenotypeca's yeast platform, particularly as a cautionary case study on scaling such platforms.
  • GlycoFi (Merck): GlycoFi, acquired by Merck in 2006, was a pioneer in glycoengineered yeast strains for therapeutic protein production. As a successful exit precedent in yeast-based protein expression platform companies, it represents a strategic comparable for Phenotypeca's category and exit trajectory.
  • Ginkgo Bioworks: Ginkgo Bioworks is a large, publicly-traded synthetic biology platform company serving pharma, agriculture, and industrial biotech customers with cell engineering services. It represents a broader, well-capitalised platform competitor to Phenotypeca's yeast strain optimisation offering, with much greater scale and scope.

Direct peers

  • Albumedix: Albumedix (formerly Novozymes Biopharma / Delta Biotechnology) is a leading supplier of recombinant human albumin (rHSA) produced in Saccharomyces cerevisiae — directly comparable to Phenotypeca's recombinant albumin strain licensing business. Their commercial product Recombumin is the closest commercial competitor in the yeast-based recombinant albumin market.
  • Delta Biotechnology: Delta Biotechnology was the original commercial developer of recombinant human serum albumin in yeast. Now operating under Albumedix, it represents the historical reference technology for the recombinant albumin category Phenotypeca is targeting with its QTL-optimised strains.
  • Novozymes (Novozymes Biopharma): Novozymes Biopharma (now part of Novonesis) is a long-established yeast-based recombinant protein manufacturer with decades of commercial biopharmaceutical supply. Comparable to Phenotypeca in yeast expression platform technology and recombinant protein production expertise, and a noted previous employer of several Phenotypeca team members.

Regional players

  • e-Therapeutics: e-Therapeutics is a UK-based drug discovery company previously led by Phenotypeca CEO Johnny Cordiner. While operating in a different therapeutic modality (network pharmacology and siRNA), it represents a relevant comparable for understanding the CEO's strategic playbook and the UK biotech capital markets environment.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Phenotypeca social profiles

Digital presence

Phenotypeca financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phenotypeca leadership team

Management profile

Number of profiles

Profiles17 records

Phenotypeca funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phenotypeca M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phenotypeca

What does Phenotypeca do?

Phenotypeca develops and licenses high-performance Saccharomyces cerevisiae production strains for recombinant protein manufacture using its proprietary Quantitative Trait Locus (QTL) strain optimisation platform. The company licenses biosimilars (Semaglutide, Recombinant Albumin, Sargramostim), develops biological therapeutics (VHH antibodies, multi-valent vaccines), supplies recombinant peptides for skincare and consumer health, and provides custom strain optimisation and process support services to pharmaceutical, biotech, CDMO and government clients.

Is Phenotypeca a public or private company?

Phenotypeca is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Phenotypeca founded?

Phenotypeca was founded in 2018. It employs 11 to 50 people.

Where is Phenotypeca based?

Phenotypeca is headquartered in Nottingham, United Kingdom, in the Europe region.

How does Phenotypeca make money?

Four revenue lines are on record. Biosimilar Licensing is the primary driver. The others are custom Strain Development Services, peptide Supply and process Support Services.

Who are Phenotypeca's main competitors?

Emerging players on record are Codexis, Cobra Biologics and Bicycle Therapeutics. Broad incumbents are Amyris, GlycoFi (Merck) and Ginkgo Bioworks. Direct peers are Albumedix, Delta Biotechnology and Novozymes (Novozymes Biopharma). e-Therapeutics is listed as a regional player.

Does Phenotypeca have an API?

No public API is recorded for Phenotypeca.

What industry is Phenotypeca in?

Phenotypeca's product category is Biopharmaceutical Manufacturing. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals